The Pre-/Post-Transplant Hepatitis C Antibody Associated with the IL-28B RS8099917 TT Genotype and miRNA-122 Expression May Protect Acute Cellular Rejection After LDLT
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Anti-HCV Antibody
2.3. IL-28B Single-Nucleotide Polymorphism
2.4. MicroRNA-122
2.5. Liver Biopsy Interpretation
2.6. Institutional Review Board Statement
2.7. Informed Consent Statement
2.8. Statistics
3. Results
3.1. The Relationship Between miRNA-122 Expression and IL-28B rs8099917
3.2. The Relationship Between Acute Cellular Rejection and IL-28B rs8099917
3.3. The Relationship Between Anti-HCV Titer and IL-28B rs8099917
3.3.1. Pre-LT Anti-HCV Titer
- Intercept: B = 29.173, indicating a predicted value of 29.173 for pre-LT anti-HCV when all other variables are zero, which is a highly significant result (p < 0.001).
- IL-28B TT: B = 23.559 (p = 0.002, 95% CI: 9.111 to 38.006, observed power = 0.895), indicating that the predicted value of pre-LT anti-HCV increased by 23.559 when IL-28B was the TT genotype, which is significant (p = 0.002).
3.3.2. Post-LT Anti-HCV Titer
- Intercept: B = 50.304, indicating a predicted value of 50.304 for post-LT anti-HCV when all other variables are zero, which is a highly significant result (p < 0.001).
- IL-28B TT: B = 29.082 (p = 0.039, 95% CI: 1.593 to 56.572, observed power = 0.550), indicating that the predicted value of post-LT anti-HCV increased by 29.082 when IL-28B was the TT genotype, which is significant (p = 0.039).
3.3.3. miRNA-122
- Intercept: B = 0.002, indicating a predicted value of 0.002 for miRNA-122 when all other variables are zero. This result is not significant (p = 0.778).
- IL-28B TT: B = 0.015 (p = 0.038, 95% CI: 0.001 to 0.030, observed power = 0.554), indicating that the predicted value of miRNA-122 increases by 0.015 when IL-28B is the TT genotype, which is significant (p = 0.038).
3.3.4. ACR
- Intercept: B = 0.625, indicating a predicted value of 0.625 for ACR when all other variables are zero, which is a highly significant result (p < 0.001).
- IL-28B TT: B = −0.349 (p = 0.022, 95% CI: −0.is to −0.053, observed power = 0.643), indicating that the predicted value of ACR was reduced by 0.349 when IL-28B is the TT genotype, which is significant (p = 0.022).
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
ALF | Acute liver failure |
ALT | Alanine aminotransferase |
AST | Aspartate aminotransferase |
HCV | Hepatitis C virus |
HCC | Hepatocellular carcinoma |
INR | International normalized ratio |
LT | Liver transplantation |
LDLT | Living-donor liver transplantation |
miRNA | MicroRNA |
SNP | Single-nucleotide polymorphism |
References
- Chigbu, D.I.; Loonawat, R.; Sehgal, M.; Patel, D.; Jain, P. Hepatitis C virus infection: Host-Virus interaction and mechanisms of viral persistence. Cells 2019, 8, 376. [Google Scholar] [CrossRef] [PubMed]
- Tang, W.; Chen, W.; Amini, A.; Boeras, D.; Falconer, J.; Kelly, H.; Peeling, R.; Varsaneux, O.; Tucker, J.D.; Easterbrook, P. Diagnostic accuracy of tests to detect Hepatitis C antibody: A meta-analysis and review of the literature. BMC Infect. Dis. 2017, 17, 695. [Google Scholar] [CrossRef]
- Ghany, M.G.; Morgan, T.R. AASLD-IDSA Hepatitis C Guidance Panel Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020, 71, 686–721. [Google Scholar] [CrossRef]
- Olivera, S.; Perez, A.; Falcon, V.; Urquiza, D.; Pichardo, D.; Martinez-Donato, G. Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice. Arch. Virol. 2020, 165, 593–607. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.Y.; Lin, Y.H.; Lin, P.J.; Tsai, P.C.; Liu, S.F.; Huang, Y.C.; Tsai, J.J.; Huang, C.I.; Yeh, M.L.; Liang, P.C.; et al. Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. PLoS ONE 2021, 16, e0254028. [Google Scholar] [CrossRef]
- Law, M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb. Perspect. Med. 2021, 11, a036962. [Google Scholar] [CrossRef] [PubMed]
- Luxenburger, H.; Neumann-Haefelin, C.; Thimme, R.; Boettler, T. HCV specific T cell responses during and after chronic HCV infection. Viruses 2018, 10, 645. [Google Scholar] [CrossRef] [PubMed]
- Osburn, W.O.; Snider, A.E.; Wells, B.L.; Latanich, R.; Bailey, J.R.; Thomas, D.L.; Cox, A.L.; Ray, S.C. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 2014, 59, 2140–2151. [Google Scholar] [CrossRef]
- Jing, J.S.; Wang, Z.Q.; Jiang, Y.K.; Zhang, X.Y.; Jiang, W.M. Association of cytokine gene polymorphisms with chronic hepatitis C virus genotype 1b infection in Chinese Han population: An observational study. Medicine 2020, 99, e22362. [Google Scholar] [CrossRef]
- Miri, H.H.; Fazeli, P.; Ali-Hassanzadeh, M.; Bemani, P.; Kabelitz, D.; Kalantar, K. Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: Systematic review and meta-analysis. Arch. Virol. 2021, 166, 2469–2478. [Google Scholar] [CrossRef]
- Hung, C.H.; Chang, K.C.; Lu, S.N.; Wang, J.H.; Chen, C.H.; Lee, C.M.; Hu, T.H. Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area. Hepatology 2013, 57, 2089–2090. [Google Scholar] [CrossRef]
- Mikulski, D.; Kościelny, K.; Dróżdż, I.; Mirocha, G.; Nowicki, M.; Misiewicz, M.; Perdas, E.; Strzałka, P.; Wierzbowska, A.; Fendler, W. Serum levels of miR-122-5p and miR-125a-5p predict hepatotoxicity occurrence in patients undergoing autologous hematopoietic stem cell transplantation. Int. J. Mol. Sci. 2024, 25, 4355. [Google Scholar] [CrossRef]
- Schmuck, R.B.; Reutzel-Selke, A.; Raschzok, N.; Morgul, H.M.; Struecker, B.; Lippert, S.; de Carvalho Fischer, C.; Schmelzle, M.; Boas-Knoop, S.; Bahra, M.; et al. Bile: miRNA pattern and protein-based biomarkers may predict acute cellular rejection after liver transplantation. Biomarkers 2017, 22, 19–27. [Google Scholar] [CrossRef]
- Koch, P.F.; Ludwig, K.; Krenzien, F.; Hillebrandt, K.H.; Schöning, W.; Pratschke, J.; Raschzok, N.; Sauer, I.M.; Moosburner, S. miRNA as potential biomarkers after liver transplantation: A systematic review. Transplant Rev (Orlando). 2024, 38, 100831. [Google Scholar] [CrossRef] [PubMed]
- Biggins, S.W.; Trotter, J.; Gralla, J.; Burton, J.R.; Bambha, K.M.; Dodge, J.; Brocato, M.; Cheng, L.; McQueen, M.; Forman, L.; et al. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J. Hepatol. 2013, 58, 969–976. [Google Scholar] [CrossRef] [PubMed]
- Chang, T.S.; Chang, K.C.; Chen, W.M.; Hsu, N.T.; Lee, C.Y.; Lin, Y.C.; Huang, W.C.; Chiu, W.N.; Hu, J.H.; Huang, T.J.; et al. Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: A population-based prospective cohort study. BMJ Open 2021, 11, e046115. [Google Scholar] [CrossRef] [PubMed]
- Augestad, E.H.; Holmboe Olesen, C.; Grønberg, C.; Soerensen, A.; Velázquez-Moctezuma, R.; Fanalista, M.; Bukh, J.; Wang, K.; Gourdon, P.; Prentoe, J. The hepatitis C virus envelope protein complex is a dimer of heterodimers. Nature 2024, 633, 704–709. [Google Scholar] [CrossRef] [PubMed]
- Shaheen, M.; Afzal, S.; Khubaib, B.; Amin, I.; Shahid, M.; Idrees, M. Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review. Crit. Rev. Eukaryot. Gene Expr. 2020, 30, 223–229. [Google Scholar] [CrossRef]
- Kamo, Y.; Ichikawa, T.; Miyaaki, H.; Uchida, S.; Yamaguchi, T.; Shibata, H.; Takuya Honda, T.; Taura, N.; Isomoto, H.; Takeshima, F.; et al. Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy. Hepatol. Res. 2015, 45, 88–96. [Google Scholar] [CrossRef]
- Torbenson, M.; Washington, K. Pathology of liver disease: Advances in the last 50 years. Hum. Pathol. 2020, 95, 78–98. [Google Scholar] [CrossRef]
- Kawaoka, T.; Takahashi, S.; Takaki, S.; Hiramatsu, A.; Waki, K.; Hiraga, N.; Miki, D.; Tsuge, M.; Imamura, M.; Kawakami, Y.; et al. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. J. Gastroenterol. Hepatol. 2012, 27, 1467–1472. [Google Scholar] [CrossRef] [PubMed]
- Yan, B.; Gao, J.; Guo, J.; Yang, D.; Li, D. Interleukin-28B dampens protease-induced lung inflammation via IL-25 and TSLP inhibition in epithelial cells. Sci. Rep. 2020, 10, 20973. [Google Scholar] [CrossRef] [PubMed]
- Echeverría, N.; Chiodi, D.; López, P.; Ciceron, A.S.; Angulo, J.; Marcelo López-Lastra, M.; Silvera, P.; Canavesi, A.; Bianchi, C.; Colistro, V.; et al. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virol. J. 2018, 15, 40. [Google Scholar] [CrossRef] [PubMed]
- Joshi, D.; Salehi, S.; Brereton, H.; Arno, M.; Quaglia, A.; Heaton, N.; O’Grady, J.; Agarwal, K.; Aluvihare, V. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. Liver Transpl. 2013, 19, 383–394. [Google Scholar] [CrossRef]
- Zhang, P.; Guo, Z.; Zhong, K.; Li, Q.; Ouyang, J.; Chen, M.; Hu, A.; Jiao, X.; Zhu, X.; He, X. Evaluation of Immune Profiles and MicroRNA Expression Profiles in Peripheral Blood Mononuclear Cells of Long-Term Stable Liver Transplant Recipients and Recipients with Acute Rejection Episodes. Transplant. Proc. 2015, 47, 2907–2915. [Google Scholar] [CrossRef]
Category | TT Group No. (%) | GT Group No. (%) | p Value |
---|---|---|---|
Cases | 29 (64.4) | 16 (35.6) | |
Gender, M/F | 17/12 | 12/4 | NS |
Age (mean ± SD) | 57.41 ± 6.65 | 59.94 ± 7.84 | NS |
Combined with HCC | 25 (86.2) | 10 (62.5) | NS |
HCV genotype (1a/1b/2/undetected) | 2/12/5/10 | 0/4/5/7 | |
Pre-LT | |||
AST | 39.69 ± 16.77 | 63.81 ± 57.88 | <0.05 |
ALT | 33.83 ± 21.17 | 67.94 ± 108.88 | NS |
Bil. T | 1.40 ± 0.72 | 2.03 ± 1.15 | <0.05 |
HCV RNA | 11 (37.9) | 6 (37.5) | NS |
Anti-HCV titer | 52.73 ± 26.52 | 29.17 ± 14.29 | <0.005 |
DAA treatment | 6 (20.7) | 5 (31.3) | NS |
Post-LT | |||
AST | 35.41 ± 22.55 | 64.13 ± 41.17 | <0.005 |
ALT | 42.62 ± 39.00 | 73.13 ± 45.98 | <0.05 |
Bil. T | 0.64 ± 0.28 | 0.69 ± 0.37 | NS |
HCV RNA | 6 (20.7) | 2 (12.5) | NS |
Anti-HCV titer | 79.39 ± 45.56 | 50.30 ± 40.21 | <0.05 |
DAA treatment | 10 (34.5) | 6 (37.5) | NS |
IL-28B SNP rs8099917 | Acute Cellular Rejection N (%) | p Value |
---|---|---|
Genotype TT, n = 29 | 8 (27.6) | 0.024 |
Genotype GT, n = 16 | 10 (62.5) |
(A) | ||||
Ranks | IL28B | N | Mean Rank | Sum of Ranks |
Pre-LT anti-HCV | TT | 29 | 26.97 | 782.00 |
GT | 16 | 15.81 | 253.00 | |
Total | 45 | |||
Post-LT anti-HCV | TT | 29 | 26.21 | 760.00 |
GT | 16 | 17.19 | 275.00 | |
Total | 45 | |||
(B) | ||||
Test Statistics (a) | Pre-LT Anti-HCV | Post-LT Anti-HCV | ||
Mann–Whitney U | 117.000 | 139.000 | ||
Wilcoxon W | 253.000 | 275.000 | ||
Z | −2.729 | −2.207 | ||
Asymp. Sig. (two-tailed) | 0.006 | 0.027 |
Effect | Value | F | Hypothesis df | Error df | Sig. | Observed Power a | |
---|---|---|---|---|---|---|---|
Intercept | Pillai’s Trace | 0.811 | 42.847 b | 4.000 | 40.000 | 0.000 | 1.000 |
Wilks’ Lambda | 0.189 | 42.847 b | 4.000 | 40.000 | 0.000 | 1.000 | |
Hotelling’s Trace | 4.285 | 42.847 b | 4.000 | 40.000 | 0.000 | 1.000 | |
Roy’s Largest Root | 4.285 | 42.847 b | 4.000 | 40.000 | 0.000 | 1.000 | |
rs8099917 | Pillai’s Trace | 0.037 | 5.074 b | 4.000 | 40.000 | 0.002 | 0.943 |
Wilks’ Lambda | 0.663 | 5.074 b | 4.000 | 40.000 | 0.002 | 0.943 | |
Hotelling’s Trace | 0.507 | 5.074 b | 4.000 | 40.000 | 0.002 | 0.943 | |
Roy’s Largest Root | 0.507 | 5.074 b | 4.000 | 40.000 | 0.002 | 0.943 |
Dependent Variable | Parameter | B | Std. Error | t | Sig. | 95% Confidence Interval | Observed Power a | |
---|---|---|---|---|---|---|---|---|
Lower Bound | Upper Bound | |||||||
Pre-LT anti-HCV | Intercept | 29.173 | 5.751 | 5.037 | 0.000 | 17.575 | 40.770 | 0.999 |
[IL-28B TT] | 23.559 | 7.164 | 3.209 | 0.002 | 9.111 | 30.006 | 0.095 | |
[IL-28B GT] | 0 b | . | . | . | . | . | . | |
Post-LT anti-HCV | Intercept | 50.304 | 10.943 | 4.597 | 0.000 | 28.236 | 72.372 | 0.994 |
[IL-28B TT] | 29.082 | 13.631 | 2.134 | 0.039 | 1.593 | 56.572 | 0.550 | |
[IL-28B GT] | 0 b | . | . | . | . | . | 0. | |
miRNA-122 | Intercept | 0.002 | 0.006 | 0.284 | 0.778 | −0.010 | 0.013 | 0.059 |
[IL-28B TT] | 0.015 | 0.007 | 2.143 | 0.038 | 0.001 | 0.030 | 0.554 | |
[IL-28B GT] | 0 b | . | . | . | . | . | . | |
ACR | Intercept | 0.625 | 0.118 | 5.307 | 0.000 | 387 | 0.863 | 0.999 |
[IL-28B TT] | −0.349 | 0.147 | −2.380 | 0.022 | −0.645 | −0.053 | 0.643 | |
[IL-28B GT] | 0b | . | . | . | . | . | . |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chiu, K.-W.; Lin, Y.-C.; Li, W.-F.; Huang, K.-T.; Hsu, L.-W.; Wang, C.-C. The Pre-/Post-Transplant Hepatitis C Antibody Associated with the IL-28B RS8099917 TT Genotype and miRNA-122 Expression May Protect Acute Cellular Rejection After LDLT. Curr. Issues Mol. Biol. 2024, 46, 12772-12783. https://doi.org/10.3390/cimb46110760
Chiu K-W, Lin Y-C, Li W-F, Huang K-T, Hsu L-W, Wang C-C. The Pre-/Post-Transplant Hepatitis C Antibody Associated with the IL-28B RS8099917 TT Genotype and miRNA-122 Expression May Protect Acute Cellular Rejection After LDLT. Current Issues in Molecular Biology. 2024; 46(11):12772-12783. https://doi.org/10.3390/cimb46110760
Chicago/Turabian StyleChiu, King-Wah, Yu-Cheng Lin, Wei-Feng Li, Kuang-Tzu Huang, Li-Wen Hsu, and Chih-Chi Wang. 2024. "The Pre-/Post-Transplant Hepatitis C Antibody Associated with the IL-28B RS8099917 TT Genotype and miRNA-122 Expression May Protect Acute Cellular Rejection After LDLT" Current Issues in Molecular Biology 46, no. 11: 12772-12783. https://doi.org/10.3390/cimb46110760